Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional) (PAR-24-273)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

The Impact of Stressors on the Biological Mechanisms of Aging and Other Aging-Associated Outcomes in Experimental Model Systems (R61/R33 Clinical Trial Not allowed) (RFA-AG-25-019)

Sponsor: National Institute on Aging

Award: For the R61 exploratory phase, the combined budget for direct costs for the two-year project period may not exceed $500,000, with no more than $250,000 requested in any single year. For the three-year R33 implementation phase, applicants' combined budget for direct costs may not exceed $1,500,000, with no more than $500,000 requested in any single year.

Due Date: November 07, 2024.

Short Courses Promoting Analyses of Data from the International Health and Retirement Study (HRS) and Harmonized Cognitive Assessment Protocol (HCAP) (R25 Clinical Trial Not Allowed) (RFA-AG-25-025)

Sponsor: National Institute on Aging

Award: Direct costs up to $350,000 per year may be requested. The maximum project period is 5 years.

Due Date: October 10, 2024.

Notice of Special Interest (NOSI): Administrative Supplement Program to Add Fluid-based Biomarkers and APOE Genotyping to NINDS ADRD Human Subjects Research Grants (NOT-NS-24-109)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: One-year administrative supplement to provide support for currently active NINDS Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) awards to add/include APOE genotype and fluid-based AD/ADRD biomarkers to ongoing AD/ADRD human subjects research studies. Individual requests can be no more than $150,000 in direct costs.

Due Date: November 11, 2024.

ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed) (PAR-24-270)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Due Date: October 04, 2024.

Notice of Intent to Publish an FOA for NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)(NOT-AG-24-060)

Sponsor: National Institute on Aging

Due Date: Estimated Publication Date of Notice of Funding Opportunity: November 01, 2024. First Estimated Application Due Date: February 12, 2025.

Notice of Intent to Publish an FOA for BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed) (NOT-NS-24-130)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Estimated Publication Date of Notice of Funding Opportunity: September 13, 2024. First Estimated Application Due Date: June 02, 2025.

Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed) (RFA-AG-25-026)

Sponsor: National Institute on Aging

Due Date: Letter of Intent due October 7, 2024. Application due November 07, 2024.

Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required (RFA-FD-25-001)

Sponsor: U.S. Food and Drug Administration

Due Date: 2024 dates: LOI due September 22, 2024; application due October 22, 2024. 2025 dates: LOI due September 21, 2025; application due October 21, 2025.

Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) (RFA-NS-24-037)

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Aging

Award: Application budgets are limited to no more than $1,000,000 in direct costs per year. The maximum project period is five years.

Due Date: November 19, 2024.

Notice of Intent to Publish a FOA for Blueprint Neurotherapeutics Network: Biologic-based Drug Discovery and Development for Nervous System Disorders (UG3/UH3 Clinical Trial Optional) (NOT-NS-24-014)

Sponsor: National Institutes of Health

Due Date: Estimated Publication Date of Notice of Funding Opportunity: October 01, 2024. First Estimated Application Due Date: January 27, 2025.

Notice of Intent to Publish a FOA for Blueprint Neurotherapeutics Network: Biologic-based Drug Discovery and Development for Nervous System Disorders (U44 Clinical Trial Optional) (NOT-NS-24-015)

Sponsor: National Institutes of Health

Due Date: Estimated Publication Date of Notice of Funding Opportunity: October 01, 2024. First Estimated Application Due Date: January 27, 2025.

McKnight Scholar Awards

Sponsor: The McKnight Endowment Fund for Neuroscience

Award: Applicants for the McKnight Scholar Awards must be independent investigators at not-for-profit research institutions in the United States and must hold a faculty position at the rank of Assistant Professor and must have served at that rank for less than five years at the application deadline. Each Scholar will receive $75,000 annually in 2025, 2026, and 2027. Funds may be used in any way that will facilitate development of the Scholar’s research program, but not for indirect costs.

Due Date: January 13, 2025 at 5 PM Central Time.

Notice of Termination of RFA-NS-24-028: BRAIN Initiative Connectivity across Scales Data Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed) (NOT-NS-24-127)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: This Notice informs the extramural community that RFA-NS-24-028 “BRAIN Initiative Connectivity across Scales Data Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed)" will be terminated. The final receipt date, August 21, 2024, has been canceled.

Notice of Intent to Publish a Funding Opportunity Announcement for Promoting Equity Through BRAIN Technology Partnerships (R34 - Clinical Trials Not Allowed) (NOT-NS-24-104)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Estimated Publication Date of Notice of Funding Opportunity: October 01, 2024. First Estimated Application Due Date: February 14, 2025.